Aligos Therapeutics presents data from eight presentations at AASLD

Aligos Therapeutics (ALGS) announced positive data from eight presentations, including one oral presentation, at the American Association for the Study of Liver Disease’s, AASLD, The Liver Meeting 2025, being held November 7 – 11, 2025 in Washington, D.C. Pevifoscorvir Sodium Post Treatment Data: Among HBeAg+ subjects, 8 of 10 subjects transitioned to NA monotherapy; of these, 6 maintained HBV DNA levels below the lower limit of quantification throughout the NA only 8-week follow-up period. In the HBeAg- subjects, 8 of 9 subjects switched to NA monotherapy, and all 8 subjects maintained HBV DNA less than LLOQ throughout the NA only 8-week follow-up period. Reductions in HBV antigen and HBV RNA were also maintained during the NA-only 8-week follow-up period. 96 Week Pevifoscorvir Sodium Monotherapy Data: In all 10 HBeAg+ subjects with very high mean baseline HBV DNA level of 8.0 log10 IU/mL, a rapid, profound, and durable HBV DNA reduction was noted following daily oral dose of 300 mg pevifoscorvir sodium monotherapy. At Week 48, 6 of 10 subjects achieved HBV DNA less than LLOQ . With treatment extension, this rate increased to 10 of 10 subjects at Week 96. Additionally, HBV DNA level declined below the undetectable level in 5 of 10 subjects at Week 96.